<DOC>
	<DOCNO>NCT00571740</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody , cetuximab bevacizumab , block tumor growth different way . Some block ability tumor cell grow spread . Others find tumor cell help kill carry tumor-killing substance . Bevacizumab may also stop growth tumor cell block blood flow tumor . Drugs use chemotherapy , oxaliplatin , leucovorin , fluorouracil , work different way stop growth tumor cell , either kill cell stop divide . Giving monoclonal antibody together combination chemotherapy may kill tumor cell . PURPOSE : This randomized phase II trial study well give cetuximab together bevacizumab work first-line therapy , follow combination chemotherapy bevacizumab without cetuximab second-line therapy treat patient stage IV colorectal cancer .</brief_summary>
	<brief_title>Cetuximab Bevacizumab First-Line Therapy Followed By Combination Chemotherapy Bevacizumab With Without Cetuximab Second-Line Therapy Treating Patients With Stage IV Colorectal Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - To assess efficacy bevacizumab cetuximab first-line treatment metastatic colorectal cancer , measure percentage patient remain progression-free 6 month . Secondary - To evaluate adverse event , confirm response , duration response , time disease progression , time treatment failure , survival patient treat bevacizumab cetuximab . - To evaluate adverse event , confirm response , duration response , time disease progression , time treatment failure , survival patient refractory dual-agent bevacizumab cetuximab subsequently treat modified FOLFOX7 chemotherapy bevacizumab without cetuximab . - To evaluate quality life parameter patient treat regimen . - To estimate direct medical resource utilization cost . - To assess reliability FDG-PET measurement early treatment response , measure percentage patient progression-free 6 month . - To identify circulate angiogenesis biomarkers . - To assay activity pro-angiogenic factor plasma angiogenic assay . OUTLINE : This multicenter study* . Patients stratify accord ECOG performance status ( 0-1 v 2 ) number metastatic site ( 1 v &gt; 1 ) . NOTE : *Participating site must PET-qualified . - First-line therapy : Patients receive bevacizumab IV 30-90 minute cetuximab IV 2 hour day 1 . Treatment repeat every 2 week absence disease progression unacceptable toxicity . Patients progressive disease proceed second-line therapy . - Second-line therapy : Patients randomized* 1 2 treatment arm . - Arm I ( modify FOLFOX7 bevacizumab ) : Patients receive bevacizumab IV 30-90 minute , oxaliplatin IV 2 hour , leucovorin calcium IV 2 hour day 1 fluorouracil IV 46 hour begin day 1 . Treatment repeat every 2 week absence disease progression unacceptable toxicity . - Arm II ( modify FOLFOX7 bevacizumab cetuximab ) : Patients receive bevacizumab modify FOLFOX7 arm I . Patients also receive cetuximab IV 2 hour day 1 . Treatment repeat every 2 week absence disease progression unacceptable toxicity . NOTE : *Randomization occur prior receive first-line therapy . Patients undergo blood sample collection periodically translational study . Samples analyze circulate endothelial cell endothelial progenitor cell via flow cytometry ; angiogenic activity serum/plasma angiogenesis-dependent disease via endothelial proliferation assay matrigel tube formation assay ; circulate angiogenesis biomarkers ( i.e. , free VEGF , soluble FLT-1 , KDR ) via ELISA . Quality life assess periodically use UNISCALE , Skindex-16 , Skin Assessment Questionnaires . After completion study treatment , patient follow every 6 month 3 year .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm stage IV colorectal cancer Measurable disease , define least one lesion whose long diameter accurately measure ≥ 2.0 cm conventional technique OR ≥ 1.0 cm spiral CT scan Must candidate neoadjuvant therapy No CNS brain metastasis PATIENT CHARACTERISTICS : ECOG performance status 02 Life expectancy ≥ 12 week ANC ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Hemoglobin ≥ 10.0 g/dL Total bilirubin &lt; 1.5 time upper limit normal ( ULN ) Alkaline phosphatase ≤ 3 time ULN AST ≤ 3 time ULN Creatinine ≤ 1.5 x time ULN Proteinuria &lt; 1+ urinalysis OR proteinuria &lt; 1 g 24hour urine collection Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Englishspeaking patient must ability complete questionnaire assistance Must willing provide blood tissue sample research purpose No history hypertensive crisis hypertensive encephalopathy No blood pressure &gt; 150/100 mm Hg No New York Heart Association ( NYHA ) class IIIV congestive heart failure No myocardial infarction unstable angina within past 6 month No stroke transient ischemic attack within past 6 month No clinically significant vascular disease ( e.g. , aortic aneurysm aortic dissection ) No clinically significant peripheral vascular disease No evidence bleed diathesis coagulopathy No significant traumatic injury within past 28 day No abdominal fistula , gastrointestinal perforation , intraabdominal abscess within past 6 month No serious nonhealing wound , ulcer , bone fracture PRIOR CONCURRENT THERAPY : No prior nonsurgical treatment stage IV disease Adjuvant therapy allow complete &gt; 6 month prior study registration More 4 week since prior concurrent plan participation another experimental drug study No prior therapy specifically directly target EGFR pathway No prior monoclonal antibody therapy More 28 day since prior major surgery open biopsy More 7 day since prior minor surgery , fineneedle aspiration core biopsy Placement vascular access device meet criterion No concurrent major surgery</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>stage IV colon cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
	<keyword>recurrent colon cancer</keyword>
	<keyword>recurrent rectal cancer</keyword>
</DOC>